Standard Clinical Pathway

Core Conclusion

The standard multiple myeloma clinical pathway spans 4 distinct phases: 4 to 6 cycles of induction quadruplets, autologous stem cell transplant consolidation, continuous lenalidomide maintenance, and routine surveillance every 1 to 3 months.

Detailed Points

• (1) Induction Therapy (The Initial Attack):

  • Goal: To rapidly reduce the number of myeloma cells in your body and relieve any symptoms.
  • For Transplant-Eligible Patients: The preferred, most effective approach today is a "quadruplet" (4-drug) combination. This typically involves Daratumumab or Isatuximab combined with Bortezomib, Lenalidomide, and Dexamethasone (known as Dara-VRd or Isa-VRd) given for 4 to 6 cycles.
  • For Transplant-Ineligible or Frail Patients: You will often receive the same highly effective quadruplet (Dara-VRd or Isa-VRd) but for a longer duration of about 9 cycles. If you are older or frail, your doctor may suggest a gentler 2- or 3-drug regimen, like Daratumumab plus Lenalidomide and Dexamethasone (Dara-Rd), tailored to your body's tolerance$^{,}$.

• (2) Timing for Stem Cell Collection (Saving Your Healthy Seeds):

  • Key Decision Point: If you are a candidate for a stem cell transplant, your team needs to harvest your healthy blood stem cells before the medications tire out your bone marrow.
  • Timeline: This collection must occur early—strictly within the first 6 cycles of induction therapy, and usually right after cycle 3 or 4$^{,}$. Prolonged exposure to drugs like Lenalidomide can damage your stem cell reserves, so doctors aim to collect enough cells early on to support at least two transplants for the future.

• (3) Autologous Stem Cell Transplant (ASCT) (The Deep Clean):

  • Key Decision Point: Transplant eligibility is based on your overall health, age, and organ function, not just a number on your chart.
  • Eligible Path: You will receive a high dose of chemotherapy (usually Melphalan at 200 mg/m²) to wipe out the stubborn, hidden myeloma cells. A day or two later, your previously collected healthy stem cells are infused back into your bloodstream to rescue and rebuild your immune system.
  • Ineligible Path: If a transplant is too risky for your body, you will safely skip this step. Instead, you will continue your induction therapy until you reach maximum benefit, and then transition smoothly into maintenance therapy.

• (4) Consolidation Therapy (Solidifying the Results):

  • Goal: For patients who undergo a transplant, doctors may want to "lock in" the deep response achieved by the procedure.
  • Regimen: This usually consists of 2 additional cycles of the exact same drug combination you received during induction (like Dara-VRd), particularly if you only received 4 or fewer cycles before your transplant.

• (5) Maintenance Therapy (Long-Term Guardianship):

  • Goal: Myeloma is treated much like a chronic illness. Maintenance is a lighter, ongoing treatment designed to keep the disease asleep for years.
  • Standard-Risk Patients: The standard of care is continuous therapy with a single oral drug—typically Lenalidomide$^{,}$.
  • High-Risk Patients: If your myeloma has aggressive genetic features, your team will likely recommend a stronger "doublet" (two-drug) maintenance. This usually pairs Lenalidomide with a proteasome inhibitor (like Bortezomib) or an anti-CD38 antibody (like Daratumumab or Isatuximab)$^{,}$.
  • Duration: To ensure the longest possible survival, maintenance therapy is generally given continuously until the disease progresses or until the side effects become intolerable$^{,}$.

The above content is sourced from the following references

• EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
• Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma
• NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma